Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, B-Cell | 6 | 2023 | 103 | 3.430 |
Why?
|
Hodgkin Disease | 12 | 2024 | 177 | 3.270 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 12 | 2023 | 151 | 3.080 |
Why?
|
Lymphoma, T-Cell, Peripheral | 5 | 2023 | 27 | 2.170 |
Why?
|
Biomarkers, Tumor | 8 | 2019 | 1461 | 1.310 |
Why?
|
Lymphoproliferative Disorders | 4 | 2023 | 107 | 1.180 |
Why?
|
Bone Marrow | 4 | 2022 | 434 | 1.140 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 136 | 1.120 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 2 | 2017 | 21 | 1.070 |
Why?
|
Mediastinal Neoplasms | 2 | 2022 | 46 | 1.030 |
Why?
|
5-Methylcytosine | 2 | 2022 | 110 | 0.960 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2023 | 189 | 0.900 |
Why?
|
Glucose Transporter Type 1 | 1 | 2022 | 20 | 0.880 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2022 | 29 | 0.870 |
Why?
|
Epstein-Barr Virus Infections | 5 | 2019 | 50 | 0.850 |
Why?
|
Lymphoma, T-Cell | 1 | 2022 | 48 | 0.830 |
Why?
|
Lymphoma, Mantle-Cell | 4 | 2021 | 35 | 0.810 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2020 | 5 | 0.780 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2017 | 173 | 0.750 |
Why?
|
STAT6 Transcription Factor | 1 | 2019 | 28 | 0.730 |
Why?
|
Leukemia | 1 | 2022 | 318 | 0.720 |
Why?
|
Bone Marrow Cells | 3 | 2019 | 253 | 0.700 |
Why?
|
Humans | 66 | 2024 | 86281 | 0.690 |
Why?
|
Reed-Sternberg Cells | 3 | 2024 | 4 | 0.640 |
Why?
|
T-Lymphocytes | 3 | 2020 | 1195 | 0.610 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2019 | 261 | 0.610 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2017 | 107 | 0.590 |
Why?
|
Erythrocyte Aggregation | 1 | 2016 | 4 | 0.570 |
Why?
|
Infectious Mononucleosis | 1 | 2016 | 6 | 0.570 |
Why?
|
Adenocarcinoma | 3 | 2008 | 1160 | 0.560 |
Why?
|
Histiocytosis, Sinus | 2 | 2019 | 14 | 0.550 |
Why?
|
Diagnosis, Differential | 9 | 2019 | 1562 | 0.550 |
Why?
|
Lymphocytes | 3 | 2023 | 461 | 0.550 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2019 | 371 | 0.530 |
Why?
|
Piperidines | 4 | 2021 | 181 | 0.500 |
Why?
|
Immunoglobulin G | 2 | 2019 | 456 | 0.490 |
Why?
|
Granulocyte Precursor Cells | 1 | 2013 | 7 | 0.480 |
Why?
|
CD11c Antigen | 1 | 2013 | 11 | 0.480 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2013 | 27 | 0.480 |
Why?
|
Cytoplasmic Granules | 1 | 2013 | 94 | 0.470 |
Why?
|
Herpesvirus 8, Human | 1 | 2013 | 11 | 0.470 |
Why?
|
Sarcoma, Kaposi | 1 | 2013 | 19 | 0.460 |
Why?
|
Castleman Disease | 1 | 2013 | 13 | 0.460 |
Why?
|
Antigens, CD | 2 | 2013 | 457 | 0.460 |
Why?
|
Bone Marrow Neoplasms | 1 | 2013 | 17 | 0.460 |
Why?
|
Middle Aged | 27 | 2021 | 24957 | 0.460 |
Why?
|
HIV Seropositivity | 1 | 2013 | 49 | 0.450 |
Why?
|
Prostatic Neoplasms | 4 | 2008 | 1708 | 0.450 |
Why?
|
Down-Regulation | 2 | 2022 | 504 | 0.440 |
Why?
|
Immunohistochemistry | 9 | 2022 | 1752 | 0.430 |
Why?
|
B-Lymphocytes | 5 | 2023 | 724 | 0.430 |
Why?
|
Monocytes | 1 | 2013 | 214 | 0.430 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2011 | 4 | 0.420 |
Why?
|
Male | 33 | 2023 | 40860 | 0.420 |
Why?
|
Integrin alpha Chains | 1 | 2011 | 14 | 0.420 |
Why?
|
Lewis X Antigen | 1 | 2011 | 9 | 0.410 |
Why?
|
Fucosyltransferases | 1 | 2011 | 8 | 0.400 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2023 | 159 | 0.400 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2011 | 16 | 0.400 |
Why?
|
Leukemia, Hairy Cell | 1 | 2011 | 186 | 0.400 |
Why?
|
Sclerosis | 1 | 2010 | 28 | 0.390 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 22 | 0.390 |
Why?
|
Dura Mater | 1 | 2010 | 44 | 0.380 |
Why?
|
Female | 30 | 2021 | 44405 | 0.380 |
Why?
|
Prognosis | 9 | 2023 | 3669 | 0.380 |
Why?
|
Autoimmune Lymphoproliferative Syndrome | 1 | 2010 | 2 | 0.380 |
Why?
|
Aged | 23 | 2021 | 18353 | 0.380 |
Why?
|
Meningeal Neoplasms | 1 | 2010 | 61 | 0.380 |
Why?
|
Histiocytic Sarcoma | 1 | 2010 | 8 | 0.380 |
Why?
|
Image Cytometry | 2 | 2007 | 12 | 0.370 |
Why?
|
Neoplasms | 2 | 2020 | 2889 | 0.360 |
Why?
|
Flow Cytometry | 5 | 2024 | 679 | 0.360 |
Why?
|
Adult | 22 | 2024 | 25577 | 0.350 |
Why?
|
Pyrimidines | 3 | 2018 | 370 | 0.340 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 380 | 0.340 |
Why?
|
DNA, Neoplasm | 4 | 2013 | 265 | 0.340 |
Why?
|
Immunophenotyping | 4 | 2019 | 211 | 0.330 |
Why?
|
Aneuploidy | 2 | 2007 | 55 | 0.330 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 2023 | 132 | 0.330 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2023 | 589 | 0.320 |
Why?
|
Neoplasm Proteins | 3 | 2019 | 532 | 0.320 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2016 | 1305 | 0.310 |
Why?
|
Lymph Nodes | 3 | 2020 | 530 | 0.300 |
Why?
|
Ploidies | 1 | 2006 | 40 | 0.290 |
Why?
|
Pyrazoles | 2 | 2018 | 153 | 0.290 |
Why?
|
Phenotype | 2 | 2023 | 2375 | 0.280 |
Why?
|
Pathology, Clinical | 1 | 2006 | 33 | 0.280 |
Why?
|
Logistic Models | 2 | 2007 | 1184 | 0.280 |
Why?
|
Neoplasm Staging | 6 | 2016 | 1932 | 0.280 |
Why?
|
Flavonoids | 1 | 2006 | 85 | 0.270 |
Why?
|
Adenine | 3 | 2021 | 85 | 0.270 |
Why?
|
Plasma Cells | 2 | 2019 | 80 | 0.270 |
Why?
|
Observer Variation | 2 | 2007 | 601 | 0.260 |
Why?
|
Statistics as Topic | 1 | 2006 | 237 | 0.260 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 2351 | 0.250 |
Why?
|
Adolescent | 9 | 2024 | 8968 | 0.250 |
Why?
|
Biopsy | 2 | 2019 | 1160 | 0.250 |
Why?
|
Biomarkers | 3 | 2023 | 1709 | 0.250 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 104 | 0.250 |
Why?
|
Lupus Erythematosus, Cutaneous | 1 | 2023 | 5 | 0.230 |
Why?
|
Cell Cycle Proteins | 1 | 2006 | 388 | 0.230 |
Why?
|
In Situ Hybridization | 4 | 2013 | 307 | 0.230 |
Why?
|
Dermatitis | 1 | 2023 | 32 | 0.230 |
Why?
|
Exanthema | 1 | 2023 | 36 | 0.230 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 878 | 0.220 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 53 | 0.220 |
Why?
|
Young Adult | 10 | 2024 | 5961 | 0.220 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 689 | 0.220 |
Why?
|
Cyclin D1 | 2 | 2016 | 83 | 0.210 |
Why?
|
Apoptosis | 2 | 2023 | 1678 | 0.210 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 1671 | 0.210 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2022 | 427 | 0.210 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 162 | 0.210 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2023 | 206 | 0.200 |
Why?
|
Cell Proliferation | 2 | 2023 | 1571 | 0.200 |
Why?
|
B7-H1 Antigen | 2 | 2023 | 250 | 0.200 |
Why?
|
Cell Nucleus | 3 | 2008 | 579 | 0.200 |
Why?
|
Cell Lineage | 1 | 2022 | 273 | 0.200 |
Why?
|
Aged, 80 and over | 9 | 2021 | 6481 | 0.200 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 241 | 0.200 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 76 | 0.190 |
Why?
|
Graft vs Host Disease | 1 | 2023 | 364 | 0.190 |
Why?
|
Spleen | 2 | 2013 | 430 | 0.190 |
Why?
|
Chromothripsis | 1 | 2020 | 5 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2434 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2020 | 24 | 0.190 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2020 | 14 | 0.180 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2019 | 4 | 0.180 |
Why?
|
Combined Modality Therapy | 4 | 2015 | 1680 | 0.180 |
Why?
|
Mastitis | 1 | 2019 | 5 | 0.180 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2009 | 376 | 0.180 |
Why?
|
Sezary Syndrome | 1 | 2019 | 8 | 0.180 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 12 | 0.180 |
Why?
|
Genomic Instability | 1 | 2020 | 79 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 369 | 0.180 |
Why?
|
Biopsy, Needle | 3 | 2012 | 234 | 0.180 |
Why?
|
Mycosis Fungoides | 1 | 2019 | 23 | 0.180 |
Why?
|
Ki-1 Antigen | 1 | 2019 | 17 | 0.180 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2019 | 49 | 0.180 |
Why?
|
Breast Diseases | 1 | 2019 | 97 | 0.170 |
Why?
|
Thymus Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
GATA3 Transcription Factor | 1 | 2019 | 48 | 0.170 |
Why?
|
Lymphadenopathy | 1 | 2019 | 16 | 0.170 |
Why?
|
Sulfonamides | 1 | 2021 | 299 | 0.170 |
Why?
|
Cervical Vertebrae | 1 | 2019 | 79 | 0.170 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2019 | 69 | 0.160 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 46 | 0.160 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 476 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 120 | 0.160 |
Why?
|
Breast | 1 | 2019 | 286 | 0.160 |
Why?
|
Mutation | 4 | 2022 | 3952 | 0.150 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2017 | 425 | 0.150 |
Why?
|
Muscle, Smooth | 2 | 2009 | 354 | 0.150 |
Why?
|
CD5 Antigens | 1 | 2016 | 14 | 0.140 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2009 | 164 | 0.140 |
Why?
|
Coombs Test | 1 | 2016 | 8 | 0.140 |
Why?
|
Burkitt Lymphoma | 1 | 2015 | 31 | 0.140 |
Why?
|
Melanoma | 1 | 2020 | 454 | 0.140 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 329 | 0.130 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 348 | 0.130 |
Why?
|
Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 35 | 0.130 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2016 | 302 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2019 | 541 | 0.130 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 272 | 0.120 |
Why?
|
Gene Expression Profiling | 2 | 2014 | 1381 | 0.120 |
Why?
|
Chediak-Higashi Syndrome | 1 | 2013 | 1 | 0.120 |
Why?
|
Leukocytosis | 1 | 2013 | 16 | 0.120 |
Why?
|
Blood Cell Count | 1 | 2013 | 79 | 0.120 |
Why?
|
HLA-DR Antigens | 1 | 2013 | 61 | 0.120 |
Why?
|
Cohort Studies | 2 | 2013 | 2759 | 0.120 |
Why?
|
Data Mining | 1 | 2013 | 42 | 0.120 |
Why?
|
Survival Rate | 2 | 2019 | 1856 | 0.120 |
Why?
|
Polymerase Chain Reaction | 2 | 2013 | 927 | 0.110 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.110 |
Why?
|
Laser Capture Microdissection | 1 | 2013 | 20 | 0.110 |
Why?
|
Cell Line, Tumor | 3 | 2023 | 2421 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 303 | 0.110 |
Why?
|
Viral Load | 1 | 2013 | 148 | 0.110 |
Why?
|
DNA, Viral | 1 | 2013 | 265 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 877 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2010 | 100 | 0.110 |
Why?
|
Gene Rearrangement | 1 | 2013 | 170 | 0.110 |
Why?
|
Pseudolymphoma | 1 | 2011 | 9 | 0.100 |
Why?
|
Cell Separation | 1 | 2011 | 196 | 0.100 |
Why?
|
Mucous Membrane | 2 | 2009 | 83 | 0.100 |
Why?
|
Urothelium | 2 | 2009 | 68 | 0.100 |
Why?
|
Clone Cells | 1 | 2010 | 213 | 0.090 |
Why?
|
Oral Ulcer | 1 | 2010 | 3 | 0.090 |
Why?
|
Herpesvirus 4, Human | 1 | 2011 | 114 | 0.090 |
Why?
|
Skin Diseases, Infectious | 1 | 2010 | 13 | 0.090 |
Why?
|
Recurrence | 3 | 2023 | 1137 | 0.090 |
Why?
|
Rituximab | 2 | 2023 | 116 | 0.090 |
Why?
|
Databases, Factual | 1 | 2013 | 808 | 0.090 |
Why?
|
Piperazines | 1 | 2012 | 272 | 0.090 |
Why?
|
Skin Ulcer | 1 | 2010 | 25 | 0.090 |
Why?
|
fas Receptor | 1 | 2010 | 75 | 0.090 |
Why?
|
Family Health | 1 | 2010 | 162 | 0.090 |
Why?
|
Fatal Outcome | 1 | 2010 | 293 | 0.090 |
Why?
|
Chromosome Aberrations | 1 | 2010 | 386 | 0.090 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 285 | 0.090 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 415 | 0.080 |
Why?
|
Myoepithelioma | 1 | 2008 | 11 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2010 | 145 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2010 | 276 | 0.080 |
Why?
|
Adenoma, Oxyphilic | 1 | 2008 | 28 | 0.080 |
Why?
|
Parotid Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
Case-Control Studies | 1 | 2013 | 1801 | 0.080 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2007 | 6 | 0.080 |
Why?
|
Muscle Proteins | 1 | 2009 | 132 | 0.080 |
Why?
|
Karyotype | 2 | 2019 | 32 | 0.080 |
Why?
|
Discriminant Analysis | 1 | 2007 | 66 | 0.080 |
Why?
|
Sarcoma, Ewing | 1 | 2007 | 42 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2009 | 222 | 0.080 |
Why?
|
Mice | 4 | 2023 | 11313 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2010 | 337 | 0.080 |
Why?
|
Germ-Line Mutation | 1 | 2010 | 329 | 0.080 |
Why?
|
Sarcoma, Synovial | 1 | 2007 | 21 | 0.080 |
Why?
|
Regression Analysis | 1 | 2008 | 595 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2007 | 27 | 0.080 |
Why?
|
Histological Techniques | 1 | 2006 | 35 | 0.070 |
Why?
|
Vaginal Smears | 1 | 2007 | 68 | 0.070 |
Why?
|
Photometry | 1 | 2006 | 14 | 0.070 |
Why?
|
Antibodies | 1 | 2009 | 349 | 0.070 |
Why?
|
Testicular Neoplasms | 1 | 2007 | 104 | 0.070 |
Why?
|
Cytogenetic Analysis | 1 | 2006 | 71 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 36 | 0.070 |
Why?
|
Signal Transduction | 3 | 2023 | 3233 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2006 | 46 | 0.070 |
Why?
|
Papillomaviridae | 1 | 2007 | 153 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 2007 | 126 | 0.070 |
Why?
|
Retinoblastoma Protein | 1 | 2006 | 66 | 0.070 |
Why?
|
Caspase 3 | 1 | 2006 | 159 | 0.070 |
Why?
|
Follow-Up Studies | 1 | 2013 | 3616 | 0.070 |
Why?
|
Urinary Bladder | 1 | 2007 | 236 | 0.070 |
Why?
|
Genetic Markers | 1 | 2006 | 476 | 0.070 |
Why?
|
Prostate-Specific Antigen | 1 | 2007 | 346 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2019 | 7949 | 0.060 |
Why?
|
Cytological Techniques | 1 | 2005 | 30 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 977 | 0.060 |
Why?
|
India | 1 | 2005 | 120 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 589 | 0.060 |
Why?
|
Papillomavirus Infections | 1 | 2007 | 239 | 0.060 |
Why?
|
ROC Curve | 1 | 2006 | 752 | 0.060 |
Why?
|
Carcinoma | 1 | 2007 | 434 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2007 | 403 | 0.060 |
Why?
|
Vincristine | 1 | 2023 | 111 | 0.060 |
Why?
|
Models, Statistical | 1 | 2007 | 574 | 0.060 |
Why?
|
bcl-X Protein | 1 | 2023 | 52 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 1 | 2007 | 645 | 0.060 |
Why?
|
Prostatectomy | 1 | 2006 | 457 | 0.060 |
Why?
|
Prednisone | 1 | 2023 | 255 | 0.060 |
Why?
|
Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2023 | 299 | 0.060 |
Why?
|
Doxorubicin | 1 | 2023 | 289 | 0.060 |
Why?
|
Prospective Studies | 2 | 2023 | 4194 | 0.060 |
Why?
|
Receptors, Immunologic | 1 | 2023 | 135 | 0.050 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 134 | 0.050 |
Why?
|
Oligopeptides | 1 | 2023 | 179 | 0.050 |
Why?
|
Animals | 4 | 2023 | 26518 | 0.050 |
Why?
|
Child | 1 | 2013 | 6913 | 0.050 |
Why?
|
Retrospective Studies | 3 | 2024 | 8431 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2024 | 295 | 0.050 |
Why?
|
Artificial Intelligence | 1 | 2023 | 294 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2006 | 1200 | 0.050 |
Why?
|
Emperipolesis | 1 | 2019 | 1 | 0.050 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2021 | 112 | 0.050 |
Why?
|
Myeloid Progenitor Cells | 1 | 2019 | 15 | 0.050 |
Why?
|
Ipilimumab | 1 | 2020 | 58 | 0.050 |
Why?
|
Risk Assessment | 1 | 2007 | 2253 | 0.050 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2020 | 110 | 0.050 |
Why?
|
Erythroid Cells | 1 | 2019 | 14 | 0.050 |
Why?
|
Megakaryocytes | 1 | 2019 | 36 | 0.050 |
Why?
|
Disease Progression | 2 | 2019 | 1531 | 0.050 |
Why?
|
S100 Proteins | 1 | 2019 | 50 | 0.040 |
Why?
|
Cell Adhesion | 1 | 2021 | 418 | 0.040 |
Why?
|
United States | 2 | 2024 | 6637 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2020 | 117 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2019 | 97 | 0.040 |
Why?
|
Gene Dosage | 1 | 2020 | 207 | 0.040 |
Why?
|
Cyclosporine | 1 | 2020 | 234 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 1040 | 0.040 |
Why?
|
Tretinoin | 1 | 2019 | 125 | 0.040 |
Why?
|
Fibrosis | 1 | 2019 | 202 | 0.040 |
Why?
|
Benzodioxoles | 1 | 2018 | 16 | 0.040 |
Why?
|
Immediate-Early Proteins | 1 | 2020 | 164 | 0.040 |
Why?
|
Staining and Labeling | 1 | 2019 | 165 | 0.040 |
Why?
|
Mortality | 1 | 2019 | 148 | 0.040 |
Why?
|
Purines | 1 | 2018 | 91 | 0.040 |
Why?
|
Histiocytes | 1 | 2017 | 22 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2023 | 2369 | 0.040 |
Why?
|
World Health Organization | 2 | 2007 | 103 | 0.040 |
Why?
|
Time Factors | 1 | 2006 | 5198 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 458 | 0.040 |
Why?
|
src Homology Domains | 1 | 2016 | 44 | 0.040 |
Why?
|
Infant | 1 | 2023 | 3036 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2019 | 1203 | 0.040 |
Why?
|
NF-kappa B | 1 | 2019 | 442 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2007 | 551 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 526 | 0.030 |
Why?
|
Genomics | 1 | 2020 | 710 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 1196 | 0.030 |
Why?
|
Blotting, Southern | 1 | 2013 | 129 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 455 | 0.030 |
Why?
|
Survival Analysis | 1 | 2016 | 1536 | 0.030 |
Why?
|
Pancytopenia | 1 | 2012 | 23 | 0.030 |
Why?
|
Imatinib Mesylate | 1 | 2012 | 126 | 0.030 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2011 | 20 | 0.030 |
Why?
|
Developed Countries | 1 | 2011 | 24 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 1056 | 0.020 |
Why?
|
Benzamides | 1 | 2012 | 226 | 0.020 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 1 | 2010 | 20 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 2010 | 53 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2010 | 66 | 0.020 |
Why?
|
Genes, Immunoglobulin | 1 | 2010 | 111 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2009 | 129 | 0.020 |
Why?
|
Fractures, Compression | 1 | 2007 | 17 | 0.020 |
Why?
|
Bone Screws | 1 | 2007 | 43 | 0.020 |
Why?
|
Pathology | 1 | 2007 | 30 | 0.020 |
Why?
|
Cytoplasm | 1 | 2008 | 281 | 0.020 |
Why?
|
Hyperplasia | 1 | 2007 | 148 | 0.020 |
Why?
|
Societies, Scientific | 1 | 2007 | 44 | 0.020 |
Why?
|
Spinal Fusion | 1 | 2007 | 85 | 0.020 |
Why?
|
Spinal Fractures | 1 | 2007 | 75 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2007 | 124 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2007 | 148 | 0.020 |
Why?
|
Aging | 1 | 2011 | 689 | 0.020 |
Why?
|
Urology | 1 | 2007 | 108 | 0.020 |
Why?
|
Age Factors | 1 | 2010 | 1842 | 0.020 |
Why?
|
Societies, Medical | 1 | 2007 | 572 | 0.010 |
Why?
|
Prostate | 1 | 2006 | 374 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 1987 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2007 | 1030 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 3347 | 0.010 |
Why?
|